Clinical Trial Update: EF-39 PANOVA-4: Study of Tumor Treating Fields Concomitant With Atezolizumab, Gemcitabine and Nab-Paclitaxel as First-LineTreatment for Metastatic Pancreatic Ductal Adenocarcinoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating Tumor Treating Fields EF-39 in combination with atezolizumab, gemcitabine, and nab-paclitaxel as first-line therapy for m…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• Atezolizumab (atezolizumab)
• Gemcitabine (Gemcitabine)
• Nab-paclitaxel (paclitaxel protein-bound)
• Tumor Treating Fields (EF-39)

Snippet

Sponsor: NovoCure Ltd. | Conditions: Metastatic Pancreatic Ductal Adenocarcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING